End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/05/15
頁 數：46頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H1 2014’, provides an overview of the End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H1 2014’, provides an overview of the End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Overview 6
Therapeutics Development 7
Pipeline Products for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Overview 7
Pipeline Products for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Comparative Analysis 8
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics under Development by Companies 9
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics under Investigation by Universities/Institutes 10
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Products under Development by Companies 13
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Products under Investigation by Universities/Institutes 14
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Companies Involved in Therapeutics Development 15
AstraZeneca PLC 15
Eli Lilly and Company 16
La Jolla Pharmaceutical Company 17
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
tabalumab - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
tenapanor - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
PINTA-745 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Recombinant Cystathionine Beta Synthase - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
LJPC-101 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Recent Pipeline Updates 35
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects 37
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Product Development Milestones 38
Featured News & Press Releases 38
Apr 23, 2014: Acceleron and Celgene Announce Interim Clinical Data for Sotatercept Demonstrating Dose Dependent Increases in Hemoglobin in Patients with End Stage Renal Disease on Hemodialysis 38
Mar 17, 2014: Acceleron and Celgene Announce Interim Clinical Data for Sotatercept in Patients with End Stage Renal Disease on Hemodialysis at the 2014 National Kidney Foundation Spring Clinical Meeting 38
Jan 13, 2014: Pharmalink Completes Enrolment of Patients into Phase IIB Clinical Study (Nefigan) of Nefecon 39
Jan 13, 2014: Ardelyx Receives $15 Million Milestone as Part of Ongoing Tenapanor Collaboration With AstraZeneca 40
Dec 18, 2013: Acceleron Earns $7 Million Milestone Payment for Celgene’s Initiation of Sotatercept Phase 2 Clinical Trial in Patients with End Stage Renal Disease on Hemodialysis 40
Jun 03, 2013: Keryx Biopharma Announces Presentation Of Zerenex Phase III Data At 2013 World Congress Of Nephrology 41
May 06, 2013: Trevi Therapeutics Commences Phase I Clinical Study Of Nalbuphine ER In End-Stage Renal Disease Patients On Hemodialysis 42
Apr 04, 2013: Shire Regenerative Medicine Initiates Two Phase II Studies Evaluating Vascugel In Patients With End-Stage Renal Disease Undergoing Arteriovenous Access Creation For Hemodialysis 43
Aug 28, 2012: Rockwell Medical Receives Canadian Patent For SFP Formulation For Iron-Delivery In Hemodialysis Patients 43
Jul 31, 2012: Rockwell Medical Completes Patient Enrollment In Phase III Clinical Trials For SFP Iron-Delivery In Hemodialysis Patients 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 46
Disclaimer 46
List of Tables
Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), H1 2014 7
Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Products under Investigation by Universities/Institutes, H1 2014 14
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by AstraZeneca PLC, H1 2014 15
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Eli Lilly and Company, H1 2014 16
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by La Jolla Pharmaceutical Company, H1 2014 17
Assessment by Monotherapy Products, H1 2014 18
Number of Products by Stage and Target, H1 2014 20
Number of Products by Stage and Mechanism of Action, H1 2014 22
Number of Products by Stage and Route of Administration, H1 2014 24
Number of Products by Stage and Molecule Type, H1 2014 26
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics - Recent Pipeline Updates, H1 2014 35
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects, H1 2014 37
List of Figures
Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), H1 2014 7
Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Products, H1 2014 12
Assessment by Monotherapy Products, H1 2014 18
Number of Products by Top 10 Target, H1 2014 19
Number of Products by Stage and Top 10 Target, H1 2014 20
Number of Products by Top 10 Mechanism of Action, H1 2014 21
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 22
Number of Products by Top 10 Route of Administration, H1 2014 23
Number of Products by Stage and Top 10 Route of Administration, H1 2014 24
Number of Products by Top 10 Molecule Type, H1 2014 25
Number of Products by Stage and Top 10 Molecule Type, H1 2014 26
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Overview 6
Therapeutics Development 7
Pipeline Products for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Overview 7
Pipeline Products for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Comparative Analysis 8
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics under Development by Companies 9
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics under Investigation by Universities/Institutes 10
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Products under Development by Companies 13
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Products under Investigation by Universities/Institutes 14
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Companies Involved in Therapeutics Development 15
AstraZeneca PLC 15
Eli Lilly and Company 16
La Jolla Pharmaceutical Company 17
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
tabalumab - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
tenapanor - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
PINTA-745 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Recombinant Cystathionine Beta Synthase - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
LJPC-101 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Recent Pipeline Updates 35
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects 37
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Product Development Milestones 38
Featured News & Press Releases 38
Apr 23, 2014: Acceleron and Celgene Announce Interim Clinical Data for Sotatercept Demonstrating Dose Dependent Increases in Hemoglobin in Patients with End Stage Renal Disease on Hemodialysis 38
Mar 17, 2014: Acceleron and Celgene Announce Interim Clinical Data for Sotatercept in Patients with End Stage Renal Disease on Hemodialysis at the 2014 National Kidney Foundation Spring Clinical Meeting 38
Jan 13, 2014: Pharmalink Completes Enrolment of Patients into Phase IIB Clinical Study (Nefigan) of Nefecon 39
Jan 13, 2014: Ardelyx Receives $15 Million Milestone as Part of Ongoing Tenapanor Collaboration With AstraZeneca 40
Dec 18, 2013: Acceleron Earns $7 Million Milestone Payment for Celgene’s Initiation of Sotatercept Phase 2 Clinical Trial in Patients with End Stage Renal Disease on Hemodialysis 40
Jun 03, 2013: Keryx Biopharma Announces Presentation Of Zerenex Phase III Data At 2013 World Congress Of Nephrology 41
May 06, 2013: Trevi Therapeutics Commences Phase I Clinical Study Of Nalbuphine ER In End-Stage Renal Disease Patients On Hemodialysis 42
Apr 04, 2013: Shire Regenerative Medicine Initiates Two Phase II Studies Evaluating Vascugel In Patients With End-Stage Renal Disease Undergoing Arteriovenous Access Creation For Hemodialysis 43
Aug 28, 2012: Rockwell Medical Receives Canadian Patent For SFP Formulation For Iron-Delivery In Hemodialysis Patients 43
Jul 31, 2012: Rockwell Medical Completes Patient Enrollment In Phase III Clinical Trials For SFP Iron-Delivery In Hemodialysis Patients 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 46
Disclaimer 46
List of Tables
Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), H1 2014 7
Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Products under Investigation by Universities/Institutes, H1 2014 14
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by AstraZeneca PLC, H1 2014 15
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Eli Lilly and Company, H1 2014 16
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by La Jolla Pharmaceutical Company, H1 2014 17
Assessment by Monotherapy Products, H1 2014 18
Number of Products by Stage and Target, H1 2014 20
Number of Products by Stage and Mechanism of Action, H1 2014 22
Number of Products by Stage and Route of Administration, H1 2014 24
Number of Products by Stage and Molecule Type, H1 2014 26
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics - Recent Pipeline Updates, H1 2014 35
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects, H1 2014 37
List of Figures
Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), H1 2014 7
Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Products, H1 2014 12
Assessment by Monotherapy Products, H1 2014 18
Number of Products by Top 10 Target, H1 2014 19
Number of Products by Stage and Top 10 Target, H1 2014 20
Number of Products by Top 10 Mechanism of Action, H1 2014 21
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 22
Number of Products by Top 10 Route of Administration, H1 2014 23
Number of Products by Stage and Top 10 Route of Administration, H1 2014 24
Number of Products by Top 10 Molecule Type, H1 2014 25
Number of Products by Stage and Top 10 Molecule Type, H1 2014 26
